Transdermal Drug Delivery Systems Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Transdermal Drug Delivery Systems Market By Application (Cardiovascular, Contraception, Pain Management / Neurological Disorders, Smoking Cessation, Others), By Technology (Electric Current, Electroporation, Radio Frequency, Thermal, Ultrasound, Others) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Global Transdermal Drug Delivery Systems Market was valued at USD 5.9 Billion in 2020 and is anticipated to grow at USD 8.3 Billion by 2027 recording a CAGR of 4.6% during the forecast period 2021-2027. Transdermal Drug Delivery Systems Market is the self-contained, discrete dosage applied in the form of patches to the intact skin and delivers medication through the controlled rate. The main aim of transdermal patches is to deliver the medication into the systemic circulation at controlled rates to minimize the intra and interpatient variation. Transdermal drug delivery methods enable systemic drug circulation and maintain clinically efficacious concentrations at a predefined pace with minimum inter-and intrapatient variation by delivering the drug through the skin. It’s a medicated adhesive bandage that sticks to the skin and releases the medicine into the bloodstream. It lessens the strain on the digestive tract and liver that comes with taking pills orally. It increases therapeutic efficacy and safety, keeps drug levels stable in the blood, and solves the drawbacks of traditional oral dosage forms and parenteral formulations.Transdermal drug delivery systems also improve patient compliance, reduce the negative side effects of a medicine induced by a momentary overdose, and are convenient with transdermally administered pharmaceuticals that only require one weak application. The potential of the transdermal drug delivery method to offer sustained blood levels with low peak-to-trough variation via a non-oral, non-injectable route of delivery is a significant scientific advantage for continued success. Furthermore, technological improvements in transdermal drug delivery systems are projected to drive market expansion in the approaching years. Transdermal patch design modification, pressure-sensitive adhesives, and permeation enhancers are examples of sophisticated technology that improve drug dispersion and increase the capacity to hold an excess amount of medicine. A passive-delivery patch is also the sole dosage form that can bridge the gap between once-daily dosing, which is handled by oral dosage forms, and once-a-week or longer dosing, which is handled by depot injectable products.

 


Global Transdermal Drug Delivery Systems Market

MARKET SUMMARY
-
4.6%
  • Study Period– 2021-2027
  • Base Year– 2020
  • CAGR– 4.6%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Transdermal Drug Delivery Systems Market

  • Transdermal Drug Delivery Systems Market is segmented based on application, technology and geography.
  • Global transdermal drug delivery systems market is primarily driven by the advantages of transdermal delivery system such as high bioavailability, less painful drug delivery system compared to conventional drug delivery systems.
  • In addition, transdermal drug delivery systems are non-invasive and have very fewer side effects. This is likely to positively impact the growth of the market.
  • Furthermore, advancements in the transdermal drug delivery systems and recent product launch expected to bolster the market growth over the forecast period.
  • However, the adaptation rates and compatibility of the many large sized drugs are expected to hamper the market growth during the forecast period.
Market Key Players
  • Novartis AG
  • Boehringer Ingelheim GmbH
  • Generex Biotechnology Corp
  • Echo Therapeutics, Inc
  • Crescita Therapeutics Inc
  • MedPharm
  • Pantec Biosolutions AG
  • Transdermal Corp.
  • Noven Pharmaceuticals, Inc.
  • Actelion Pharmaceuticals Ltd
  • Johnson & Johnson Limited
  • 3M Pharmaceuticals Inc.
  • Mylan Pharmaceuticals Inc.
  • GlaxoSmithKline plc
Growth

Transdermal Drug Delivery Systems Market

Global transdermal drug delivery systems market expected to grow at significant rates owing to the factors such as increase R&D to advance the transdermal drug delivery systems. Companies operating in the market are adopting acquisitions and mergers as these key strategies to leverage market share. For instance, in December 2016, Luye Pharma Group has acquired TDDS business from Acino international AG to expand its R&D and product portfolio. Furthermore, market also experiencing new product launches and advent of technologically advanced products. For instance, the 3M company has launched 3MScotchpakWhite release liners and white backing films aimed to improve the use of topical products.


North-America Got Significant Share

Transdermal Drug Delivery Systems Market

Geographically, the global melanoma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The North America transdermal drug delivery systems market is expected to grow at significant rates due to the presence of key market players and increase in the number of surgical procedures and prevalence of cardiovascular disorders. According to American Heart Association, incidence of heart disease in U.S. is about 58000 in 2014. Europe transdermal drug delivery system market is expected to grow at notable rates owing to prevalence of the cardiovascular disorders and growing R&D investments in development of transdermal drug delivery systems. Asia Pacific transdermal drug delivery systems market is expected to have lucrative growth opportunity owing to development of healthcare infrastructure, growing R&D investments, and growing awareness related to the advantages of transdermal drug delivery systems.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015 to 2020) and forecast (2021 to 2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Transdermal Drug Delivery Systems Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Novartis AG (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Generex Biotechnology Corp. (Canada)
  • Echo Therapeutics, Inc. (U.S.)
  • Crescita Therapeutics Inc (Canada)
  • MedPharm (U.K.)
  • Pantec Biosolutions AG (Liechtenstein)
  • Transdermal Corp. (U.S.)
  • Noven Pharmaceuticals, Inc. (U.S.)
  • Actelion Pharmaceuticals Ltd (Switzerland)
  • Johnson & Johnson Limited (U.S.)
  • 3M Pharmaceuticals Inc. (U.S.)
  • Mylan Pharmaceuticals Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)

Description

Global Transdermal Drug Delivery Systems Market was valued at USD 5.9 Billion in 2020 and is anticipated to grow at USD 8.3 Billion by 2027 recording a CAGR of 4.6% during the forecast period 2021-2027. Transdermal Drug Delivery Systems Market is the self-contained, discrete dosage applied in the form of patches to the intact skin and delivers medication through the controlled rate. The main aim of transdermal patches is to deliver the medication into the systemic circulation at controlled rates to minimize the intra and interpatient variation. Transdermal drug delivery methods enable systemic drug circulation and maintain clinically efficacious concentrations at a predefined pace with minimum inter-and intrapatient variation by delivering the drug through the skin. It’s a medicated adhesive bandage that sticks to the skin and releases the medicine into the bloodstream. It lessens the strain on the digestive tract and liver that comes with taking pills orally. It increases therapeutic efficacy and safety, keeps drug levels stable in the blood, and solves the drawbacks of traditional oral dosage forms and parenteral formulations.Transdermal drug delivery systems also improve patient compliance, reduce the negative side effects of a medicine induced by a momentary overdose, and are convenient with transdermally administered pharmaceuticals that only require one weak application. The potential of the transdermal drug delivery method to offer sustained blood levels with low peak-to-trough variation via a non-oral, non-injectable route of delivery is a significant scientific advantage for continued success. Furthermore, technological improvements in transdermal drug delivery systems are projected to drive market expansion in the approaching years. Transdermal patch design modification, pressure-sensitive adhesives, and permeation enhancers are examples of sophisticated technology that improve drug dispersion and increase the capacity to hold an excess amount of medicine. A passive-delivery patch is also the sole dosage form that can bridge the gap between once-daily dosing, which is handled by oral dosage forms, and once-a-week or longer dosing, which is handled by depot injectable products.

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX